Please Wait...

Information Brief at Alzheimer's Association Gala in Washington, DC

Following on the theme of Alzheimer’s disease, there is a great summary paper from last month on the facts and figures (1) of this disease. Much of this was used as the information brief at the Alzheimer’s Association Gala in Washington, DC. Some of the facts are quite surprising, e.g. it is estimated that 5.4 million Americans have AD. Every 69 seconds someone in America develops Alzheimer’s disease. Total payments in 2011 for health care, long term care and hospital services for people age 65 years and older with AD and other dementias are estimated at $183 million.

Without wishing to get political, $183M is a huge sum of money for just one year of support for this chronic disease that is also now ranked as the 6th highest cause of death in the USA (2). Furthermore, as this second brief paper by Thies states, federal funding for cancer is about $6B annually, cardiovascular funding $4B, HIV $3B while Alzheimer’s disease is federally funded at $480M per year. Since the year 2000 to 2008, the incidence of Alzheimer’s disease has increased by 60% and the treatment and prevention of this debilitating condition is still a huge unmet medical need.

There are a number of therapies in development and BioClinica is involved in supporting the imaging component of many of these programs. With that said, the history of drug development in this field is littered with failures, in part because we still do not have a good handle on the etiology of conversion of those with mild cognitive impairment to Alzheimer’s disease. The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is starting to have data that will hopefully unlock many of the unknowns about this devastating disease. For those of us with a familial history of the disease and have seen it first hand, a cure cannot come too soon.

Have any questions about imaging therapies in development for Alzheimers’ disease? Please ask them in the comments below.

References:

  1. Alzheimer’s Association Report
    2011 Alzheimer’s Disease Facts & Figures
    by Alzheimer’s Association
    in Alzheimer’s & Dementia 7 (2011) 208-244
  2. Stopping a thief and killer: Alzheimer’s disease crisis demands greater commitment to research.
    Thies, W.
    Alzheimer’s & Dementia 7 (2011) 175-176

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

RT @ACROhealth: @MaryWolleyRA Mary Woolley @ResearchAmerica: 80% have heard of #clinicaltrials. 75% think trial participation is as importa…
bioclinica (5 days ago)
#Pharma & CROs: Ck it out! Enterprise tools for site payments automation & reconciliation. https://t.co/LFri5Kv0WC
bioclinica (5 days ago)
Can having a geographically diverse network of high performing sites mean fewer sites are needed in a trial? Can ha… https://t.co/tZYvWrNzHg
bioclinica (5 days ago)
Confidence is a good thing ─ especially in the clinical supply chain for global clinical trials. Here’s how accurat… https://t.co/70VwXCwuWw
bioclinica (6 days ago)
#Pharmacovigilance: Get up-to-speed on latest ind. trends & best practices + hear how others R meeting today's most… https://t.co/3YNpB9hTXs
bioclinica (2 weeks ago)
Announcing our new Chief of Staff @bioclinica Adrienne Rossi! Also welcoming President Bioclinica Site Network Eliz… https://t.co/toB9yk534k
bioclinica (2 weeks ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen